Status
Conditions
Treatments
About
A prospective, multi-center, single-arm, open-label, observational, post-market clinical follow-up. The expected duration of the study is 8 years (including up to 5-years' follow-up). Each subject will be followed up per standard of care (SoC) at each study site.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Subject has any non-target intracranial aneurysm treated within 30 days prior to study enrollment
Subject has a planned treatment of a non-target aneurysm in the same vascular territory during participation in the study within 12 months post procedure
Subject has undergone previous treatment where it would interfere with the delivery and/ or placement and/or proper apposition of Surpass Evolve FDS
Subject has acute target aneurysm rupture and/or subarachnoid hemorrhage occurred within 30 days prior to enrollment
Subject has any condition demonstrated as Warning or Precautions in IFU
Antiplatelet and/or anticoagulation therapy (e.g. aspirin and clopidogrel) is contraindicated for the subject
Subject has not received dual anti-platelet agents prior to the procedure
Subject with an active bacterial infection
Subject in whom the angiography demonstrates the anatomy is not appropriate for endovascular treatment, due to conditions such as:
Female subjects who are pregnant/ nursing, or who are unwilling or unable to take adequate method of contraception prior to the 12-month study follow-up.*
*If the subject becomes pregnant during her participation, the physician will have to evaluate the risk associated to her continuing participation to the rest of the study.
Enrollment in another trial involving an investigational product and/or drug interfere with study procedure/ results
The investigator determined that the health of the patient may be compromised by the patient's enrollment
Loading...
Central trial contact
Mingyao Zheng
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal